Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

AstraZeneca PLC

Healthcare GB AZN

14686.0GBX
244.00(1.69%)

Last update at 2026-03-10T15:48:00Z

Day Range

14526.0014790.00
LowHigh

52 Week Range

9409.5115730.38
LowHigh

Fundamentals

  • Previous Close 14442.00
  • Market Cap233978.72M
  • Volume972700
  • P/E Ratio30.92
  • Dividend Yield2.14%
  • EBITDA19280.00M
  • Revenue TTM58739.00M
  • Revenue Per Share TTM37.90
  • Gross Profit TTM 47993.00M
  • Diluted EPS TTM4.88

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 12402.00M 8509.52M 7015.27M 2501.00M -265.00000M
Minority interest -8.00000M -6.00000M -6.00000M -5.00000M -3.00000M
Net income 10225.00M 6888.10M 6055.36M 3288.00M 112.00M
Selling general administrative 19933.00M 19669.00M 17683.00M 18955.00M 95.00M
Selling and marketing expenses 579.00M 555.00M 539.00M 18955.00M 15680.00M
Gross profit 48106.00M 39698.37M 34447.94M 31960.00M 24980.00M
Reconciled depreciation 5733.00M 6688.00M 4934.00M 5480.00M 6530.00M
Ebit 14096.00M 9898.89M 8178.55M 3757.00M 1056.00M
Ebitda 19829.00M 14858.13M 13195.71M 9327.00M 7565.00M
Depreciation and amortization 5733.00M 4959.24M 5017.15M 5570.00M 6509.00M
Non operating income net other - - - - -
Operating income 13743.00M 12521.95M 9569.61M 3757.00M 1056.00M
Other operating expenses 44996.00M 40421.94M 37013.46M 40594.00M 36361.00M
Interest expense 1694.00M 1361.95M 1151.08M 1346.00M 1300.00M
Tax provision 2169.00M 1650.00M 938.00M -792.00000M -380.00000M
Interest income 360.00M 458.00M 301.00M 95.00M 43.00M
Net interest income -1334.00000M -1284.00000M -1288.00000M -1251.00000M -1257.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2169.00M 1615.55M 953.81M -792.00000M -380.00000M
Total revenue 58739.00M 52943.89M 46583.07M 44351.00M 37417.00M
Total operating expenses 34363.00M 27176.42M 24878.33M 28203.00M 23924.00M
Cost of revenue 10633.00M 13245.52M 12135.13M 12391.00M 12437.00M
Total other income expense net -1341.00000M -4012.42900M -2554.33600M -1256.00000M -1321.00000M
Discontinued operations - - - - -
Net income from continuing ops 10233.00M 7041.00M 5961.00M 3293.00M 115.00M
Net income applicable to common shares - - - 3288.00M 112.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 114074.00M 104035.00M 101119.00M 96483.00M 105363.00M
Intangible assets 37846.00M 37177.00M 38089.00M 39307.00M 42387.00M
Earning assets - - - - -
Other current assets 84.05M 1789.18M 1718.32M 11489.00M 105.00M
Total liab 65355.00M 63164.00M 61953.00M 59425.00M 66076.00M
Total stockholder equity 48667.00M 40786.00M 39143.00M 37037.00M 39268.00M
Deferred long term liab - - - - -
Other current liab 767.00M 20325.00M 20014.00M 1711.00M 1763.00M
Common stock 388.00M 388.00M 388.00M 387.00M 387.00M
Capital stock 388.00M 388.00M 388.00M 387.00M 387.00M
Retained earnings 10972.00M 3160.00M 1502.00M -574.00000M 1710.00M
Other liab - - - 8499.00M 13011.00M
Good will 21242.00M 21025.00M 19878.18M 19820.00M 19997.00M
Other assets - - - 4172.00M 5327.00M
Cash 5711.00M 5482.44M 5790.53M 6166.00M 6329.00M
Cash and equivalents - - - - -
Total current liabilities 30617.00M 27866.00M 30542.00M 26293.00M 22594.00M
Current deferred revenue - - - - -
Net debt 23911.00M 24626.00M 22567.00M 23066.00M 24452.00M
Short term debt 3486.00M 2495.00M 5185.00M 5542.00M 1893.00M
Short long term debt 3104.00M 2156.00M 5129.00M 5314.00M 1660.00M
Short long term debt total 29622.00M 30114.00M 28407.00M 29232.00M 30781.00M
Other stockholder equity 37307.00M 37238.00M 37253.00M 37224.00M 37171.00M
Property plant equipment - - - 9449.00M 10171.00M
Total current assets 28723.00M 25800.81M 24841.77M 22593.00M 26244.00M
Long term investments - - - - -
Net tangible assets - - - -22090.00000M -23116.00000M
Short term investments 30.00M 165.83M 120.97M 239.00M 69.00M
Net receivables 16340.95M 13080.72M 11833.90M 10521.00M 10758.00M
Long term debt 24715.00M 26506.00M 22365.00M 22965.00M 28134.00M
Inventory 6557.00M 5282.64M 5378.05M 4699.00M 8983.00M
Accounts payable 25280.00M 3640.00M 3267.00M 19040.00M 18938.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -949.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -2.09100M 457.59M 385.84M 1148.00M 1066.00M
Deferred long term asset charges - - - - -
Non current assets total 85351.00M 78208.00M 76065.00M 73890.00M 79119.00M
Capital lease obligations 1803.00M 1452.00M 1128.00M 953.00M 987.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -98.00000M -7980.00000M -4064.00000M -2960.00000M 605.00M
Change to liabilities - - - 1165.00M 1405.00M
Total cashflows from investing activities -6808.00000M -7980.00000M -4064.00000M -2960.00000M -11058.00000M
Net borrowings -1650.00000M 1809.00M -965.00000M -1441.00000M 7654.00M
Total cash from financing activities -7544.00000M -3996.00000M -6567.00000M -6823.00000M 3649.00M
Change to operating activities - - - - 2021.00M
Net income 12402.00M 8691.00M 6899.00M 2501.00M -265.00000M
Change in cash 269.00M -208.00000M -346.00000M -55.00000M -1508.00000M
Begin period cash flow 5429.00M 5637.00M 5983.00M 6038.00M 7546.00M
End period cash flow 5698.00M 5429.00M 5637.00M 5983.00M 6038.00M
Total cash from operating activities 14575.00M 11861.00M 10345.00M 9808.00M 5963.00M
Issuance of capital stock -481.00000M -43.00000M 33.00M 29.00M 29.00M
Depreciation 5733.00M 5065.00M 4934.00M 5480.00M 6530.00M
Other cashflows from investing activities -2660.00000M -2141.00000M -1517.00000M 60.00M 54.00M
Dividends paid 4971.00M 4629.00M 4481.00M 4364.00M 3856.00M
Change to inventory -755.00000M -131.00000M -669.00000M 3941.00M 1577.00M
Change to account receivables - -1624.00000M -1425.00000M -1349.00000M -961.00000M
Sale purchase of stock - - 3709.00M -920.00000M 12413.00M
Other cashflows from financing activities -442.00000M -1133.00000M -1154.00000M -297.00000M -178.00000M
Change to netincome - - - -2491.00000M -615.00000M
Capital expenditures 5905.00M 4586.00M 3778.00M 2571.00M 2200.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1137.00000M -893.00000M 300.00M 3757.00M 2021.00M
Stock based compensation - - 579.00M - -
Other non cash items -2423.00000M -1002.00000M -2367.00000M -1930.00000M -2323.00000M
Free cash flow 8670.00M 7275.00M 6567.00M 7237.00M 3763.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AZN
AstraZeneca PLC		 244.00 1.69% 14686.00 30.92 19.30 3.98 6.38 5.68 17.12
GSK
GlaxoSmithKline PLC		 35.00 1.71% 2081.00 9.79 9.19 2.01 4.53 2.48 7.65

Reports Covered

Stock Research & News

View All

Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

Key Executives

Name Title Year Born
Mr. Pascal Soriot D.V.M., M.B.A. CEO & Exec. Director 1959
Dr. Aradhana Sarin M.D. CFO & Exec. Director 1975
Mr. Marc Dunoyer CEO of Alexion & Chief Strategy Officer 1952
Ms. Pam P. Cheng EVP of Operations & Information Technology and Member of External Sustainability Advisory Board 1971
Mr. Chris Sheldon Head of Investor Relations NA
Mr. Jeffrey Pott Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board NA
Ms. Katarina Ageborg EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board NA
Gonzalo Vina Head of Global Media Relations NA
Dr. Menelas Pangalos Ph.D. EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board 1967
Dr. Ruud Dobber Ph.D. Exec. Vice-Pres of BioPharmaceuticals Bus. Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.